Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
Philip G. Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
Drug Safety (2021) Vol. 44, Iss. 5, pp. 515-530
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
Yoshiya Tanaka, Yiming Luo, John J. O’Shea, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 3, pp. 133-145
Open Access | Times Cited: 338
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition
Yiming Luo, Madison Alexander, Massimo Gadina, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 911-925
Open Access | Times Cited: 88
Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs
Yoshiya Tanaka
Lara D. Veeken (2021) Vol. 60, Iss. Supplement_6, pp. vi12-vi20
Open Access | Times Cited: 63
JAK inhibitors for asthma
Steve N. Georas, Patrick Donohue, Margaret Connolly, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 953-963
Open Access | Times Cited: 59
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
William J. Sandborn, Geert R. D’Haens, Bruce E. Sands, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 3, pp. 338-351
Open Access | Times Cited: 58
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
Eduardo Mysler, Gerd R Burmester, Christopher D. Saffore, et al.
Advances in Therapy (2024) Vol. 41, Iss. 2, pp. 567-597
Open Access | Times Cited: 9
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events
Fabiola Atzeni, Călin D. Popa, Valeria Nucera, et al.
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 3, pp. 233-244
Closed Access | Times Cited: 36
Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
Maurizio Benucci, Arianna Damiani, Maria Infantino, et al.
Pharmacological Research (2022) Vol. 183, pp. 106359-106359
Closed Access | Times Cited: 30
Current therapeutic overview and future perspectives regarding the treatment of psoriasis
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113388-113388
Closed Access | Times Cited: 5
Toward Overcoming Treatment Failure in Rheumatoid Arthritis
Zhuqian Wang, Jie Huang, Duoli Xie, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 32
Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis
Susmita Srivastava, Mahaboobkhan Rasool
Life Sciences (2022) Vol. 298, pp. 120516-120516
Closed Access | Times Cited: 21
Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research
Mingyo Kim, Yong‐Ho Choe, Sang‐Il Lee
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Kevin Winthrop, Séverine Vermeire, Millie D. Long, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 1, pp. 85-96
Open Access | Times Cited: 19
Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis
Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Alexandros A. Drosos
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 5, pp. 485-493
Closed Access | Times Cited: 17
Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study
Andrew J.K. Östör, Eugen Feist, Prodromos Sidiropoulos, et al.
Arthritis Research & Therapy (2025) Vol. 27, Iss. 1
Open Access
Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk
Saba Ahmed, Benna Jacob, Steven E. Carsons, et al.
Pharmaceuticals (2021) Vol. 15, Iss. 1, pp. 11-11
Open Access | Times Cited: 23
Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box
Durga Prasanna Misra, Gaurav Pande, Vikas Agarwal
Clinical Rheumatology (2022) Vol. 42, Iss. 2, pp. 621-632
Closed Access | Times Cited: 15
Neutrophils in the pathogenesis of rheumatic diseases
Jia Tong Loh, Kong‐Peng Lam
Rheumatology and Immunology Research (2022) Vol. 3, Iss. 3, pp. 120-127
Open Access | Times Cited: 15
Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study
Po‐Ku Chen, Shih‐Hsin Chang, Yi‐Ming Chen, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 8, pp. 2503-2511
Closed Access | Times Cited: 3
Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
Antibodies (2024) Vol. 13, Iss. 3, pp. 76-76
Open Access | Times Cited: 3
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
Kunihiro Yamaoka, Yoshiya Tanaka, Hideto Kameda, et al.
Drug Safety (2021) Vol. 44, Iss. 6, pp. 711-722
Open Access | Times Cited: 18
Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review
Kevin Winthrop, John D. Isaacs, Leonard H. Calabrese, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152120-152120
Open Access | Times Cited: 12
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial
R. Fleischmann, Alan Friedman, Edit Drescher, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e395-e406
Open Access | Times Cited: 8
Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis
S Chandrashekara
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 8, pp. 741-748
Closed Access | Times Cited: 1
Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
Jiayu Yuan, Hongxia Lu, Xulei Zuo, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 10
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top